Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis

Current Opinion in Investigational Drugs

Volumn 11, Issue 9, 2010, Pages 1066-1073

  Raja, Shahzad G ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACT 064992; ACT 132577; AMBRISENTAN; ANTIHYPERTENSIVE AGENT; BOSENTAN; DRUG METABOLITE; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; KETOCONAZOLE; MACITENTAN; PACLITAXEL; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; SELEXIPAG; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FIBROSING ALVEOLITIS; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PATHOGENESIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; MALE; PYRIMIDINES; RATS; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 77956242973     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ N ENGL J MED 1993 328 24 1732-1739
2. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6- dimethoxypyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J J PHARMACOL EXP THER 1997 282 3 1312-1318
3. The ETa receptor antagonist LU-135252 prevents the progression of established pulmonary hypertension induced by monocrotaline in rats. Dupuis J, Prie S J CARDIOVASC PHARMACOL THER 1999 4 1 33-39
4. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary heart artery disease. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, Jones CR, Clozel M, Meier B, Luscher TF CIRCULATION 1998 98 21 2235-2240
5. Cloning and expression of a cDNA encoding an endothelin receptor. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S NATURE 1990 348 6303 730-732
6. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T NATURE 1990 348 6303 732-735
7. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Dupuis J, Stewart DJ, Cernacek P, Gosselin G CIRCULATION 1996 94 7 1578-1584
8. Polar secretion of endothelin-1 by cultured endothelial cells. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR J BIOL CHEM 1992 267 23 16066-16068
9. Endothelin receptors in cultured adult rat cardiac fibroblasts. Katwa LC, Guarda E, Weber KT CARDIOVASC RES(1993) 27(12) 2125-2129
10. Endothelin system: The double-edged sword in health and disease. Kedzierski RM, Yanagisawa M ANNU REV PHARMACOL TOXICOL 2001 41 851-876
11. Highlights on endothelins: A review. Ortega Mateo A, de Artinano AA PHARMACOL RES 1997 36 5 339-351
12. Profile of past and current clinical trials involving endothelin receptor antagonists: The novel "-sentan" class of drug. Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE EXP BIOL MED 2006 231 6 653-695
13. Actelion-1 - first tissue-targeting endothelin receptor antagonist - in phase III for pulmonary hypertension. Actelion Ltd PRESS RELEASE 2006 December 11
14. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM EUR RESPIR J 2007 30 2 338-344
15. Phase III study initiated with Actelion-1 - highly potent tissue-targeting endothelin receptor antagonist; largest study ever in PAH to demonstrate morbidity/mortality benefits. Actelion Ltd PRESS RELEASE 2007 December 19
16. Pharmacokinetics and pharmacodynamics of the endothelin-1 receptor antagonist ACT-064992 in healthy human subjects. Sidharta PN, Dingemanse J, van Giersbergen PLM J CLIN PHARMACOL 2007 47 9 Abs 85
17. Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist ACT-064992 in healthy human subjects. Sidharta PN, Dingemanse J J CLIN PHARMACOL 2008 48 9 Abs 66
18. Pharmacolgy of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B et al J PHARMACOL EXP THER 2008 327 3 736-745
19. FDA: Cumulative list of all products that have received Orphan Designation. The Food and Drug Administration COMPANY PUBLICATION 2009 May 05
20. NCT00903331: Macitentan use in an idiopathic pulmonary fibrosis clinical study (MUSIC). CLINICALTRIALS.GOV Actelion Ltd 2009
21. Committee for Orphan medicinal products November 2009 plenary meeting monthly report. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2009 November 05
22. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Kummer O, Haschke M, Hammann F, Bodmer M, Bruderer S, Regnault Y, Dingemanse J, Krahenbuhl S EUR J PHARM SCI 2009 38 4 384-388
23. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. Sidharta PN, Dietrich H, Dingemanse J BR J CLIN PHARMACOL(2009) 68( 5) 788-789
24. Company website: Actelion. Actelion Ltd COMPANY WORLD WIDE WEB SITE 2010 February
25. Nippon Shinyaku, Actelion to codevelop macitentan for PAH. PHARMA JPN 2010 2178 March 01 21
26. Nippon Shinyaku props up marketing structure for PAH products. PHARMA JPN 2010 2179 March 08 4
27. Nippon Shinyaku enters into a license agreement with Actelion on a novel PAH development compound. Nippon Shinyaku Co Ltd PRESS RELEASE 2010 February 17
28. The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. Swigris JJ, Brown KK BIODRUGS 2010 24 1 49-54
29. A cytokine reborn Endothelin-1 in pulmonary inflammation and fibrosis. Teder P, Noble PW AM J RESPIR CELL MOL BIOL 2000 23 1 7-10
30. Abundance of endothelin-3 in rat intestine, pituitary-gland and brain. Matsumoto H, Suzuki N, Onda H, Fujino M BIOCHEM BIOPHYS RES COMMUN 1989 164 1 74-80
31. Biosynthesis, distribution and metabolism of endothelins in the pulmonary system. Battistini B, Dussault P PULM PHARMACOL THER 1998 11 2-3 79-88
32. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS J EXP MED 1990 172 6 1741-1748
33. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q LANCET 1993 341 8860 1550-1554
34. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Sessa WC, Kaw S, Hecker M, Vane JR BIOCHEM BIOPHYS RES COMMUN 1991 174 2 613-618
35. Subcellular mechanisms of endothelin action in vascular system. Masaki T, Miwa S, Sawamura T, Ninomiya H, Okamoto Y EUR J PHARMACOL 1999 375 1-3 133-138
36. Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity. Berti F, Rossoni G, Della Bella D, Villa LM, Buschi A, Trento F, Berti M, Tondo C J CARDIOVASC PHARMACOL 1993 22 2 321-326
37. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Filep JG, Bodolay E, Sipka S, Gyimesi E, Csipo I, Szegedi G CIRCULATION 1995 92 10 2969-2974
38. The endothelin system in pulmonary hypertension. Michel RP, Langleben D, Dupuis J CAN J PHYSIOL PHARMACOL( 2003) 81(6) 542-554
39. Endothelin receptor antagonists in pulmonary arterial hypertension. Dupuis J, Hoeper MM EUR RESPIR J 2008 31 2 407-415
40. Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension. Bressollette E, Dupuis J, Bonan R, Doucet S, Cernacek P, Tardif JC CHEST 2001 120 3 809-815
41. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, Hoeffken G CHEST 2001 120 5 1562-1569
42. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, Wharton J AM J RESPIR CRIT CARE MED 2002 165 3 398-405
43. EndothelinA receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension. Prie S, Stewart DJ, Dupuis J CIRCULATION(1998) 97( 21) 2169-2174
44. Ambrisentan, a non-peptide endothelin receptor antagonist. Vatter H, Seifert V CARDIOVASC DRUG REV 2006 24 1 63-76
45. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G et al EUR HEART J 2004 25 24 2243-2278
46. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV CHEST 2007 131 6 1917-1928
47. Endothelin receptor antagonists for pulmonary arterial hypertension. Liu C, Chen J COCHRANE DATABASE SYST REV( 2006) 3 CD004434
48. Does targeting the lipophilic milieu provide advantages for an endothelin antagonist? Pollock DM, Boesen EI, Black SM MOL INTERVENT 2009 9 2 75-78
49. Actelion announces second quarter 2010 financial results. Actelion Ltd PRESS RELEASE 2010 July 20
50. Clinical development. Actelion Ltd COMPANY COMMUNICATION 2010 June
51. Severe growth retardation and juvenile lethality in ET-2 knockout mice. Baynash A, Hammer R, Richardson J, Yanagisawa M INT CONF ENDOTHELIN1997 5 September 12